Related references
Note: Only part of the references are listed.Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
Tian Zhou et al.
BIOMATERIALS (2018)
Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1
Tristan D. McPherson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents
Rajith K. R. Rajoli et al.
CLINICAL PHARMACOKINETICS (2018)
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors
Anthony T. Podany et al.
CLINICAL PHARMACOKINETICS (2017)
Multimodal imaging approach to examine biodistribution kinetics of Cabotegravir (GSK1265744) long acting parenteral formulation in rat
Beat M. Jucker et al.
JOURNAL OF CONTROLLED RELEASE (2017)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
Martin Markowitz et al.
LANCET HIV (2017)
Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women
Christine Trezza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251
Chasity D. Andrews et al.
AIDS (2017)
Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA)
Kerri J. Penrose et al.
JOURNAL OF INFECTIOUS DISEASES (2016)
Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam
Melinda J. Reese et al.
XENOBIOTICA (2016)
Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans
Gary David Bowers et al.
XENOBIOTICA (2016)
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy
Andrew Owen et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
The promise and pitfalls of long-acting injectable agents for HIV prevention
Raphael J. Landovitz et al.
CURRENT OPINION IN HIV AND AIDS (2016)
Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects
Yu Lou et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection
Tae Eun Park et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2015)
The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge
Jessica Radzio et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
Chasity D. Andrews et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Cabotegravir long-acting for HIV-1 prevention
Chasity D. Andrews et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Formulation and pharmacology of long-acting cabotegravir
Christine Trezza et al.
CURRENT OPINION IN HIV AND AIDS (2015)
Antiviral Characteristics of GSK1265744, an HIV Integrase Inhibitor Dosed Orally or by Long-Acting Injection
Tomokazu Yoshinaga et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
Chasity D. Andrews et al.
SCIENCE (2014)
Cause-Specific Life Expectancies After 35 Years of Age for Human Immunodeficiency Syndrome-Infected and Human Immunodeficiency Syndrome-Negative Individuals Followed Simultaneously in Long-term Cohort Studies, 1984-2008
Nikolas Wada et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2013)
Effects of Etravirine on the Pharmacokinetics of the Integrase Inhibitor S/GSK1265744
Susan L. Ford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744
Susan L. Ford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
W. Spreen et al.
HIV CLINICAL TRIALS (2013)
Long-acting injectable antiretrovirals for HIV treatment and prevention
William R. Spreen et al.
CURRENT OPINION IN HIV AND AIDS (2013)
The survival benefits of AIDS treatment in the United States
Rochelle P. Walensky et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Share Paper
